Special Issue

Innovations in Radiation Oncology

Message from the Guest Editor

The field of radiation oncology has been revolutionized by recent innovations in technology, allowing for increasingly personalized clinical care. Artificial intelligence (AI)-based tools have been leveraged to improve efficiency with auto-contouring and planning, and the use of machine learning has led to improved outcome predictions. Additionally, the advancement of precision medicine has been supported by the recent integration of radiomics, biomarkers such as ctDNA, and genomics in treatment decisions. Furthermore, adaptive radiotherapy and real-time imaging innovations seen with MR-linacs, CBCT-based adaptation and real-time motion monitoring have transformed the way radiation is being delivered. The modern era of radiation has been characterized by the evolution of novel, innovative technology and the goal of this Special Issue is to stimulate research interests in this rapidly transforming landscape with the hope of further personalizing patient care, improving oncologic outcomes, and reshaping clinical radiation oncology.

Guest Editor

Dr. Caressa Hui

Department of Radiation Oncology, University of California, Irvine, CA, USA

Deadline for manuscript submissions

31 March 2026

MDPI

Biomedicines

**an Open Access Journal
by MDPI**

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).